Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIMUS 002 neoadjuvant umbrella study in resectable or borderline resectable pancreatic ductal carcinoma
2016-004156-29Phase 2Unknown
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- May 2018
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of oxaliplatin, fluorouracil, folinic acid, nab-paclitaxel and gemcitabine in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by NHS Greater Glasgow and Clyde. Primary endpoint: Disease progression after FOLFOX-A induction treatment. Status: unknown.
02
Drugs
oxaliplatinfluorouracilfolinic acidnab-paclitaxelgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2016-004156-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004156-29.